

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/601,324 06/20/2003 Ciaran N. Cronin SYR-EPHA2-5001-C1 4969 32793 12/15/2005 EXAMINER 7590 TAKEDA SAN DIEGO, INC. TALAVERA, MIGUEL A 10410 SCIENCE CENTER DRIVE ART UNIT PAPER NUMBER SAN DIEGO, CA 92121 1656

DATE MAILED: 12/15/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Office Action Summary	10/601,324	CRONIN ET AL.
	Examiner	Art Unit
	Miguel A. Talavera	1656
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).		
Status		
 1) Responsive to communication(s) filed on 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. 		
Disposition of Claims		
 4) Claim(s) 1-25 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-25 are subject to restriction and/or election requirement. 		
Application Papers		
 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 		
Priority under 35 U.S.C. § 119	•	
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 		
Attachment(s)		
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	

DETAILED ACTION

Application Status

1. Claims 1-25 are pending in the instant application.

Restriction

- 2. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
- For purposes of restricting the claims, the examiner has interpreted claim 16 as meaning a composition comprising at least a portion of a protein encoded by the nucleic acid of SEQ ID NO:2. If this interpretation is incorrect, applicant is requested to clarify the record.
 - I. Claims 1-17 drawn to a composition comprising a protein in crystalline form wherein the protein comprises Ephrin receptor A2 (EPHA2; SEQ ID NO: 1) or a portion of the protein has at least 90% identity with residues 605-883 of SEQ ID NO: 1, a composition comprising an isolated protein consisting of SEQ ID NO: 3 or at least a portion of a protein encoded by the nucleic acid of SEQ ID NO: 2. and methods for producing a crystal of a protein, classified in class 436, subclass 4.
 - II. Claims 18-25, drawn to computer-assisted methods of identifying one or more entities that associate with a protein by using the three-dimensional structure of said protein, wherein the identified entities are further used for detecting any *in*

Art Unit: 1656

vitro and in vivo modulation of the protein's activity, classified in class 702,

Page 3

subclass 27.

3. The inventions are distinct, each from the other because of the following reasons:

The protein of Group I and the method of Group II are related as product and process of

use. The inventions can be shown to be distinct if either or both of the following can be shown:

(1) the process for using the product as claimed can be practiced with another materially

different product or (2) the product as claimed can be used in a materially different process of

using that product (M.P.E.P. § 806.05(h)). In the instant case the protein of Group I can be used

as an antigen to elicit antibodies.

M.P.E.P. §803 sets forth two criteria for a proper restriction between patentably distinct

inventions: (A) The inventions must be independent or distinct as claimed and (B) There must be

a serious burden on the examiner. As shown above, the inventions of Groups I-II are independent

or distinct, thus satisfying the first criterion for a proper restriction. M.P.E.P. § 803 additionally

states that a serious burden on the examiner may be prima facie shown if the examiner shows by

appropriate explanation either separate classification, separate status in the art, or a different field

of search. In view of the recited limitations of the claims of each invention, a separate sequence

and/or patent and non-patent literature search for each Group is required. As such, co-

examination of the inventions of Groups I-II would require a serious burden on the examiner.

Notice of Possible Rejoinder

4. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of M.P.E.P. § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 C.F.R. § 1.116; amendments submitted after allowance are governed by 37 C.F.R. § 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 C.F.R. § 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. § 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on

Art Unit: 1656

the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. § 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See M.P.E.P. § 804.01.

Election

5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 C.F.R. § 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1 .48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 C.F.R. § 1 1.48(b) and by the fee required under 37 C.F.R. § 1.17(i).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Miguel A. Talavera whose telephone number is (571) 272-3354. The examiner can normally be reached on M-F, 8:30am-5:00pm.

Application/Control Number: 10/601,324

Art Unit: 1656

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Kathleen M. Kerr can be reached on (571) 272-0931. The fax phone number for the

organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

DAVID J. STEADMAN, PH.D.

Page 6

Miguel A. Talavera, Ph.D.

November 30, 2005